MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Novartis AG

Închisă

112.41 1.45

Rezumat

Modificarea prețului

24h

Curent

Minim

110.38

Maxim

114.32

Indicatori cheie

By Trading Economics

Venit

-369M

2.8B

Vânzări

386M

14B

P/E

Medie Sector

18.992

63.778

EPS

1.98

Randament dividend

3.47

Marjă de profit

20.8

Angajați

75,883

EBITDA

-426M

5.2B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+0.21% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.47%

2.39%

Statistici piață

By TradingEconomics

Capitalizare de piață

6.9B

221B

Deschiderea anterioară

110.96

Închiderea anterioară

112.41

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Novartis AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 feb. 2025, 06:57 UTC

Achiziții, Fuziuni, Preluări

Novartis to Buy Anthos Therapeutics for Up to $3.08 Billion

31 ian. 2025, 09:49 UTC

Câștiguri

Novartis Expects Further Profit, Sales Growth Despite Competition Threat -- 2nd Update

31 ian. 2025, 08:06 UTC

Câștiguri

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales -- Update

31 ian. 2025, 06:32 UTC

Câștiguri

Novartis Expects Further Profit, Growth After Key Drugs Boost Sales

17 mar. 2025, 07:34 UTC

Market Talk

Novartis Growth Outlook Clouded by Patent Expiries, Pipeline Concerns -- Market Talk

4 mar. 2025, 18:45 UTC

Câștiguri

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction -- IBD

11 feb. 2025, 09:25 UTC

Top știri
Achiziții, Fuziuni, Preluări

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion -- Update

11 feb. 2025, 06:42 UTC

Top știri
Achiziții, Fuziuni, Preluări

Novartis to Buy Anthos Therapeutics for Up to $3.08 Bln

11 feb. 2025, 06:22 UTC

Achiziții, Fuziuni, Preluări

Novartis: Acquisition Is Aligned With Strategic Focus on Cardiovascular Therapeutic Area

11 feb. 2025, 06:20 UTC

Achiziții, Fuziuni, Preluări

Novartis: Abelacimab's Lead Indication Is Prevention of Stroke, Systemic Embolism

11 feb. 2025, 06:19 UTC

Achiziții, Fuziuni, Preluări

Novartis: Anthos Is Developing Abelacimab, Currently in Late-Stage Trials

11 feb. 2025, 06:18 UTC

Achiziții, Fuziuni, Preluări

Novartis: Deal Is Expected to Close in 1H of 2025

11 feb. 2025, 06:18 UTC

Achiziții, Fuziuni, Preluări

Novartis Aims to Bolster Late-Stage Cardiovascular Pipeline With Acquisition

11 feb. 2025, 06:17 UTC

Achiziții, Fuziuni, Preluări

Novartis: Deal Includes Potential Additional Payments of Up to $2.15B

11 feb. 2025, 06:16 UTC

Achiziții, Fuziuni, Preluări

Novartis to Buy Anthos Therapeutics for $925M Upfront

11 feb. 2025, 06:15 UTC

Achiziții, Fuziuni, Preluări

Novartis to Buy Anthos Therapeutics

4 feb. 2025, 15:16 UTC

Top știri

Novartis Sets High Bar in Pursuit of Obesity Deals, CEO Says -- Interview

4 feb. 2025, 08:12 UTC

Market Talk
Câștiguri

Novartis Outlook Indicates No Patent Cliff Beyond 2025 -- Market Talk

31 ian. 2025, 13:56 UTC

Câștiguri

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker -- IBD

31 ian. 2025, 09:59 UTC

Acțiuni populare

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

31 ian. 2025, 07:50 UTC

Market Talk

Novartis's Outlook Exceeds Market Views -- Market Talk

31 ian. 2025, 07:46 UTC

Market Talk
Câștiguri

Novartis's Results Beat Could Clear Gap Between Mid-Term Outlook and Market Views -- Market Talk

31 ian. 2025, 06:03 UTC

Câștiguri

Novartis Expects 2025 Core Operating Profit Growth of High Single to Low Double-Digit at Constant Currency

31 ian. 2025, 06:02 UTC

Câștiguri

Novartis Expects 2025 Net Sales Growth of mid- to high-single Digit at Constant Currency

31 ian. 2025, 06:02 UTC

Câștiguri

Novartis Issues 2025 View

31 ian. 2025, 06:02 UTC

Câștiguri

Novartis Raises Dividend to CHF3.50 Vs CHF3.30

31 ian. 2025, 06:02 UTC

Câștiguri

Novartis 4Q Oper Pft $3.53B

31 ian. 2025, 06:02 UTC

Câștiguri

Novartis 4Q Net Pft $2.82B

31 ian. 2025, 06:02 UTC

Câștiguri

Analysts Saw Novartis 4Q Core Operating Profit at $4.44B

31 ian. 2025, 06:02 UTC

Câștiguri

Novartis 4Q Core Operating Profit $4.86B

Comparație

Modificare preț

Novartis AG Așteptări

Obiectiv de preț

By TipRanks

0.21% sus

Prognoză pe 12 luni

Medie 111 USD  0.21%

Maxim 125 USD

Minim 97 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovartis AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

109.97 / 112.06Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.